Generated by AI
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics for serious viral diseases. The company’s current programs target the replication mechanisms of norovirus, influenza, coronaviruses, and hepatitis C, with an emphasis on oral direct-acting candidates designed for treatment and prevention settings. Its pipeline includes drug development efforts that span discovery, preclinical work, and clinical-stage studies, supported by structure-based technologies aimed at identifying differentiated antiviral compounds. Cocrystal Pharma also engages in research partnerships and funding activities that help advance its antiviral portfolio and related scientific programs. Headquartered in Bothell, Washington, Cocrystal Pharma plays a specialized role in the biotechnology market by addressing unmet needs in infectious disease therapeutics through targeted antiviral innovation.
Website19805 North Creek Parkway
Bothell, WA, 98011
United States
The latest articles about COCP.
No serious adverse events reported to date Preliminary efficacy results expected in late 2026 or early 2027 MIAMI, Fla. And BOTHELL, Wash., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced that the last subject has been dosed in its Phase 1b norovirus challenge study (NCT07198139) evaluating CDI-988
Summary of Aug 3's posts. Generated by AI.
Summary of Apr 6's posts. Generated by AI.
Summary of Apr 6's posts. Generated by AI.
Investors talking about COCP also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.